GlassScriptPhysician profile
Naser W Azar
NPI 1700956331
$3,089.51
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $306 · 2020: $295 · 2021: $457 · 2022: $712 · 2023: $992 · 2024: $328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,319 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,318.74 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $556.51 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $465.23 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $425.85 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $362.61 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Redhill Biopharma INC. | $237.93 | 2021-2023 | Talicia, Aemcolo, Movantik |
| Merck Sharp & Dohme LLC | $152.46 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Abbott Laboratories | $119.10 | 2021-2023 | Freestyle Libre 3 |
| Pfizer INC. | $88.75 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $85.55 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $81.03 | 2022 | |
| Abbvie INC. | $76.73 | 2021-2024 | |
| Phadia US INC. | $54.90 | 2023-2024 | Immunocap |
| Otsuka America Pharmaceutical, INC. | $54.76 | 2023 | Jynarque |
| Dexcom, INC. | $54.21 | 2022 | |
| Exact Sciences Corporation | $50.56 | 2023-2024 | Cologuard Collection Kit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $29.61 | 2022 | |
| Bard Peripheral Vascular, INC. | $27.35 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.32 | 2019-2020 | |
| Tactile Systems Technology INC | $19.12 | 2020 | |
| Amgen INC. | $17.17 | 2020 | |
| Amarin Pharma, INC. | $16.87 | 2020 | |
| Hologic Sales and Service, LLC | $16.44 | 2022 | |
| Janssen Pharmaceuticals, INC | $15.04 | 2019 | |
| Sanofi Pasteur INC. | $14.94 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.00 | 2021 | |
| Genentech USA, INC. | $13.60 | 2020 | |
| Mannkind Corporation | $12.08 | 2019 | |
| Travere Therapeutics, INC. | $0.79 | 2023 | Cholbam |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naser Azar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.